/ Report Details / Pulmonary Arterial Hypertension (PAH) Market

Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) Analysis, Share, Trends, Size, & Forecast From 2014 2025

Report Code: AV199

Industry: Healthcare

Publiced On: 2020-12-11

Pages: 108

Format: ppt pdf

REPORT HIGHLIGHT

The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.

Market Dynamics

According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.

The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives.  This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.

Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.

Drug Class Takeaway

In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.

Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025

analystview report
Regional Takeaway

Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.

Key Vendor Takeaway

Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.

The market size and forecast for each segment and sub-segments has been considered as below:

  • Historical Year – 2014 & 2016
  • Base Year – 2017
  • Estimated Year – 2018
  • Projected Year – 2025

TARGET AUDIENCE

  • Traders, Distributors, and Suppliers
  • Manufacturers
  • Hospitals
  • Government and Regional Agencies and Research Organizations
  • Consultants
  • Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

  • Prostacyclin and Analogs
  • Soluble Guanylyl Cyclase (SGC) Stimulators
  • Endothelin receptor antagonist (ERA)
  • Phosphodiesterase-5

MARKET, BY REGION

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Rest of APAC
  • Rest of the World
    • Middle East and Africa
    • Latin America

TABLE OF CONTENT/

1. PULMONARY ARTERIAL HYPERTENSION MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. PULMONARY ARTERIAL HYPERTENSION KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. PULMONARY ARTERIAL HYPERTENSION INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Market Attractiveness Analysis
4.3. Regulatory Framework Analysis
5. PULMONARY ARTERIAL HYPERTENSION MARKET LANDSCAPE
5.1. Market Share Analysis
6. PULMONARY ARTERIAL HYPERTENSION MARKET – BY DRUG CLASS
6.1. Overview
6.2. Prostacyclin and Analogs
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.3. Soluble Guanylyl Cyclase (SGC) Stimulators
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.4. Endothelin receptor antagonist (ERA)
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.5. Phosphodiesterase-5
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7. PULMONARY ARTERIAL HYPERTENSION MARKET– BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.2.3. U.S.
7.2.3.1. Overview
7.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.2.4. Canada
7.2.4.1. Overview
7.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3. Europe
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3.3. France
7.3.3.1. Overview
7.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3.4. Germany
7.3.4.1. Overview
7.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3.5. Rest of Europe
7.3.5.1. Overview
7.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4. Asia Pacific (APAC)
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4.3. China
7.4.3.1. Overview
7.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4.4. India
7.4.4.1. Overview
7.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4.5. Rest of APAC
7.4.5.1. Overview
7.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5. Rest of the World
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5.3. Latin America
7.5.3.1. Overview
7.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5.4. Middle East and Africa
7.5.4.1. Overview
7.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8. KEY VENDOR ANALYSIS
8.1. Pfizer, Inc.
8.1.1. Company Overview
8.1.2. SWOT Analysis
8.1.3. Key Developments
8.2. GlaxoSmithKline
8.2.1. Company Overview
8.2.2. SWOT Analysis
8.2.3. Key Developments
8.3. Novartis
8.3.1. Company Overview
8.3.2. SWOT Analysis
8.3.3. Key Developments
8.4. Bayer
8.4.1. Company Overview
8.4.2. SWOT Analysis
8.4.3. Key Developments
8.5. Merck
8.5.1. Company Overview
8.5.2. SWOT Analysis
8.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
9. 360 DEGREE ANALYSTVIEW
10. APPENDIX
10.1. Research Methodology
10.2. Abbreviations
10.3. Disclaimer
10.4. Contact Us

List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PEST Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global Pulmonary Arterial Hypertension Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
Table 10 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 – 2025 (USD Billion)
Table 11 Pulmonary Arterial Hypertension Market, by Geography, 2014 – 2025 (USD Billion)
Table 12 North America Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 13 U.S. Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 14 Canada Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 15 Europe Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 16 France Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 17 Germany Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 18 Asia Pacific Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 19 China Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 20 India Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 21 Latin America Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 22 MEA Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)

List of Figures
Figure 1 Research Methodology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Regulatory Framework Analysis
Figure 5 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 – 2025 (USD Billion)
Figure 6 Pulmonary Arterial Hypertension Market, by Geography, 2014 – 2025 (USD Billion)

Choose License Type
assit assit

Tailor made solution just for you

80% of our clients seek made-to-order reports. how do you want us to tailor yours?
📧 Talk to Analyst

We have 24/7 dedicated support team.

Get in Touch

© 2023. All rights reserved: AnalystView Market Insights